drugset / Trial / NCT03208426

Sequential Versus Quadruple Therapy in the Second-line Treatment

NCT03208426 ↗

Phase 4 Unknown 240 enrolled National Taiwan University Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Objectives: A recent randomized trial showed that 14-day sequential therapy containing high dose proton pump inhibitor was higher than 95% in the first line treatment. However, whether the 14-day sequential therapy is more effective than 10-day bismuth quadruple therapy remains unknown. Therefore, the investigators aimed to compare the eradication rates and long term re-infection rates of sequential therapy for 14 days versus bismuth quadruple therapy for 10 days in the second line treatment.

Timeline

Start
2017-10-01
Primary completion
2019-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1000 mg —
Comparator BISMUTH OXIDE Unknown 120 mg —
Subject Clarithromycin Small molecule 500 mg —
Subject Esomeprazole Small molecule 40 mg —
Subject Metronidazole Small molecule 500 mg —
Comparator Tetracycline Unknown 500 mg —